Global Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine)), by Age Group (Pediatric and Adolescent, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 20,183.1 Million in 2022 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing adoption of inorganic strategies such as agreement and acquisitions by the key players in the market is expected to drive the market growth over the forecast period. For instance, in January 2021, Amneal Pharmaceuticals LLC., a pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products, acquired and signed a definitive agreement with Kashiv Specialty Pharmaceuticals, LLC, under which Amneal Pharmaceuticals LLC., acquire 98 % of Kashiv Specialty Pharmaceuticals, LLC, a wholly-owned subsidiary of Kashiv. With this agreement ,a team of world class R&D scientists with a proven track record of developing complex generic products (e.g. Yuvafem and EluRyng), as well as a platform of innovative drug delivery technologies will be added to Amneal Pharmaceuticals LLC.,.
Global Attention Deficit Hyperactivity Disorder Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a significance impact on the global attention deficit hyperactivity disorder treatment market, owing to the increasing behavioral and ADHD-related symptoms by the ADHD patients. For instance, in January 2022, a review paper was published by Iranian Journal of Psychiatry, according to which during the COVID-19, adolescents and children with ADHD are reported with increased behavioral and ADHD-related symptoms while there is overall decreased in the psychological well-being. Both the children and their caregivers faced psychological issues related with school lockdowns and homeschooling.
Thus, increasing the behavioral and ADHD-related symptoms by the ADHD patients in COVID-19 infection is expected to drive the market growth over the forecast period.
Global Attention Deficit Hyperactivity Disorder Treatment Market: Key Developments
In October 2020, Cingulate, a biopharmaceutical company, announced the pivotal phase 2 results for the lead candidate CTx-1301 at American Association of Child and Adolescent psychiatry annual meeting. Crossover study was done to establish safety, tolerability dose proportionality and comparative bioavailabilty of CTx-1301 and Focalin XR. The results suggested the extended duration, fast onset action and the potential for elimination for booster doses. The further phase 3 trial for CTx-1301, ensures the pharmacokinetic and pharmacodynamics relationship of stimulants for ADHD and its efficacy lasts the entire active day with the potential to minimize or prevent the afternoon wear off effects. In October 2021, Pfizer Inc., one of the biopharmaceutical company, announced the acquisition of NextWave Pharmaceuticals, Inc., a pharmaceutical company and an agreement for approved Quillivant XR, the First Once-Daily Liquid medication for Attention Deficit Hyperactivity Disorder Treatment in the U.S. NextWave Pharmaceuticals, Inc., is a developer of Quillivant XR (methylphenidate hydrochloride), and has also received the U.S. Food and Drug Adminitration (FDA), approval for the same. This agreement will primarily focused on expansion of established products and developed a high quality medicines for ADHD patients.
Browse 35 Market Data Tables and 38 Figures spread through 181 Pages and in-depth TOC on “Global Attention Deficit Hyperactivity Disorder Treatment Market”- Forecast to 2030, Global Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine)), by Age Group (Pediatric and Adolescent, Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Moreover, increasing prevalence of attention deficit hyperactivity disorder is expected to drive the market growth over the forecast period. For instance, in April 2022, a paper was published by The International Board of Credentialing and Continuing Education Standards (IBCCES), and a systematic review and meta-analysis was done, according to which around one in seven adults patients of psychiatric outpatient clinics has symptoms of ADHD while more than 5 times the rate found in the general population, globally .
Key Takeaways of the Global Attention Deficit Hyperactivity Disorder Treatment Market:
- The global attention deficit hyperactivity disorder treatment market is expected to exhibit a CAGR of 7.1% during the forecast period due to the increasing adoption of strategies such as collaborations and partnerships by the key players for carrying out research activities in attention deficit hyperactivity disorder treatment. For instance, in December 2020, Tris Pharma, Inc., a pharmaceutical company, announced partnership to commercialize Tris Quillivant XR and Quillichew ER in Europe with Neuraxpharm, a European pharmaceutical company for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders. Whereas Neuraxpharm, received exclusive rights to commercialize Tris’ FDA-approved Quillivant XR and Quillichew ER in Europe.
- Among the age group, pediatric and adolescent segment is estimated to hold a dominant position in the global attention deficit hyperactivity disorder treatment market over the forecast period, owing to the increased in the diagnosis and treatment of the ADHD. For instance, according to data provided by CDC (Centers for Disease Control and Prevention) in August 2022, about 3 in 4 children in the U.S. with ADHD are treated for ADHD and about 9.8% of children aged 3-17 have been diagnosed with ADHD.
- Among regions, North America is estimated to account for the largest market share in the global attention deficit hyperactivity disorder treatment market over the forecast period, owing to the growing personal expenditure on healthcare in the U.S. For instance, in 2020, data related to growing personal expenditure on healthcare was published by American Medical Association, according to which the expenditure of Health spending in the U.S. increased by 9.7% in 2020 to US$ 4.1 trillion or US$ 12,530 per capita. This growth rate is substantially higher than 2019 (4.3 percent) and this substantial acceleration in spending can be attributed to increases in government spending to manage the unprecedented COVID-19 pandemic.
Major players operating in the global attention deficit hyperactivity disorder treatment market include Amneal Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P., Adlon Therapeutics L.P., Cingulate, Tris Pharma, Inc., Neuraxpharm, Supernus Pharmaceuticals, Inc., Aytu Biopharma, Inc.
